×

ITEP-CMT

 

IMMUNOTEP FOR PATIENTS WITH MEDULLARY THYROID CARCINOMA (ITEP-CMT)
Type d'étude :
Phase I-II
Promoteur :
CHU Nantes
Etat actuel de l'étude :
Clos aux inclusions
Principale publication :

Bodet-Milin , J Nucl Med. – 2016

Pharmacokinetic and Imaging Optimization Study of Pretargeted Immuno-PET Using the Anti-CEA x Anti-HSG TF2 Bispecific Antibody and 68Ga-IMP-288 Peptide in Patients With Recurrences of Medullary Thyroid Carcinoma. Fermé aux inclusions

© 2015-2025 GTE  | Mentions légales